{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:14:22Z","timestamp":1783980862826,"version":"3.55.0"},"reference-count":81,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To predict potential drugs for COVID-19 by using molecular docking for virtual screening of drugs approved for other clinical applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>SARS-CoV-2 is the betacoronavirus responsible for the COVID-19 pandemic. It was listed as a potential global health threat by the WHO due to high mortality, high basic reproduction number, and lack of clinically approved drugs and vaccines. The genome of the virus responsible for COVID-19 has been sequenced. In addition, the three-dimensional structure of the main protease has been determined experimentally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To identify potential drugs that can be repurposed for treatment of COVID-19 by using molecular docking based virtual screening of all approved drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A list of drugs approved for clinical use was obtained from the SuperDRUG2 database. The structure of the target in the apo form, as well as structures of several target-ligand complexes, were obtained from RCSB PDB. The structure of SARS-CoV-2 Mpro determined from X-ray diffraction data was used as the target. Data regarding drugs in clinical trials for COVID-19 was obtained from clinicaltrials.org. Input for molecular docking based virtual screening was prepared by using Obabel and customized python, bash, and awk scripts. Molecular docking calculations were carried out with Vina and SMINA, and the docked conformations were analyzed and visualized with PLIP, Pymol, and Rasmol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the drugs that are being tested in clinical trials for COVID-19, Danoprevir and Darunavir were predicted to have the highest binding affinity for the Main protease (Mpro) target of SARS-CoV-2. Saquinavir and Beclabuvir were identified as the best novel candidates for COVID-19 therapy by using Virtual Screening of drugs approved for other clinical indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Protease inhibitors approved for treatment of other viral diseases have the potential to be repurposed for treatment of COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1386207323666200814132149","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T15:07:15Z","timestamp":1597417635000},"page":"716-728","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3394-9795","authenticated-orcid":true,"given":"Sekhar","family":"Talluri","sequence":"first","affiliation":[{"name":"Department of Biotechnology, GITAM, Visakhapatnam,India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"Wu F.","year":"2020","unstructured":"Wu F.; Zhao S.; Yu B.; Chen Y-M.; Wang W.; Song Z-G.; Hu Y.; Tao Z-W.; Tian J-H.; Pei Y-Y.; Yuan M-L.; Zhang Y-L.; Dai F-H.; Liu Y.; Wang Q-M.; Zheng J-J.; Xu L.; Holmes E.C.; Zhang Y-Z.; A new coronavirus associated with human respiratory disease in China. Nature 2020,579(7798),265-269","journal-title":"Nature"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijid.2020.01.050","volume":"92","author":"Zhao S.","year":"2020","unstructured":"Zhao S.; Lin Q.; Ran J.; Musa S.S.; Yang G.; Wang W.; Lou Y.; Gao D.; Yang L.; He D.; Wang M.H.; Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int J Infect Dis 2020,92,214-217","journal-title":"Int J Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"Li G.","year":"2020","unstructured":"Li G.; De Clercq E.; Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020,19(3),149-150","journal-title":"Nat Rev Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"Lai C.C.","year":"2020","unstructured":"Lai C.C.; Shih T.P.; Ko W.C.; Tang H.J.; Hsueh P.R.; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020,55(3),105924-105924","journal-title":"Int J Antimicrob Agents"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/tmi.13383","volume":"25","author":"Velavan T.P.","year":"2020","unstructured":"Velavan T.P.; Meyer C.G.; The COVID-19 epidemic. Trop Med Int Health 2020,25(3),278-280","journal-title":"Trop Med Int Health"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","year":"2020","unstructured":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol Coronaviridae Study Group of the International Committee on Taxonomy of Viruses2020,5(4),536-544","journal-title":"Nat Microbiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"Zhu N.","year":"2020","unstructured":"Zhu N.; Zhang D.; Wang W.; Li X.; Yang B.; Song J.; Zhao X.; Huang B.; Shi W.; Lu R.; Niu P.; Zhan F.; Ma X.; Wang D.; Xu W.; Wu G.; Gao G.F.; Tan W.; Investigating C.N.C.; Team R.; a novel coronavirus from patients with pneumonia in china, 2019. N Engl J Med China novel coronavirus investigating and research team2020,382(8),727-733","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"Zhou P.","year":"2020","unstructured":"Zhou P.; Yang X-L.; Wang X-G.; Hu B.; Zhang L.; Zhang W.; Si H-R.; Zhu Y.; Li B.; Huang C-L.; Chen H-D.; Chen J.; Luo Y.; Guo H.; Jiang R-D.; Liu M-Q.; Chen Y.; Shen X-R.; Wang X.; Zheng X-S.; Zhao K.; Chen Q-J.; Deng F.; Liu L-L.; Yan B.; Zhan F-X.; Wang Y-Y.; Xiao G-F.; Shi Z-L.; A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020,579(7798),270-273","journal-title":"Nature"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"Lu H.","year":"2020","unstructured":"Lu H.; Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020,14(1),69-71","journal-title":"Biosci Trends"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","volume":"133","author":"Fan H-H.","year":"2020","unstructured":"Fan H-H.; Wang L-Q.; Liu W-L.; An X-P.; Liu Z-D.; He X-Q.; Song L-H.; Tong Y-G.; Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J (Engl) 2020,133(9),1051-1056","journal-title":"Chin Med J (Engl)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.12688\/f1000research.22211.2","volume":"9","author":"Kruse R.L.","year":"2020","unstructured":"Kruse R.L.; Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000 Res 2020,9,72-72","journal-title":"F1000 Res"},{"key":"ref=12","first-page":"E002","volume":"43","author":"Li H.","year":"2020","unstructured":"Li H.; Wang Y.M.; Xu J.Y.; Cao B.; [Potential antiviral therapeutics for 2019 Novel Coronavirus Zhonghua Jie He He Hu Xi Za Zhi 2020,43(0),E002-E002","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev.pa.27.040187.001205","volume":"27","author":"Marshall G.R.","year":"1987","unstructured":"Marshall G.R.; Computer-aided drug design. Annu Rev Pharmacol Toxicol 1987,27,193-213","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.257.5073.1078","volume":"257","author":"Kuntz I.D.","year":"1992","unstructured":"Kuntz I.D.; Structure-based strategies for drug design and discovery. Science 1992,257(5073),1078-1082","journal-title":"Science"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1039\/C5MD00490J","volume":"7","author":"Cichero E.","year":"2016","unstructured":"Cichero E.; Espinoza S.; Tonelli M.; Franchini S.; Gerasimov A.S.; Sorbi C.; Gainetdinov R.R.; Brasili L.; Fossa P.; A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists. MedChemComm 2016,7(2),353-364","journal-title":"MedChemComm"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/14756366.2016.1256881","volume":"32","author":"Cichero E.","year":"2017","unstructured":"Cichero E.; Tonelli M.; Novelli F.; Tasso B.; Delogu I.; Loddo R.; Bruno O.; Fossa P.; Benzimidazole-based derivatives as privileged scaffold developed for the treatment of the RSV infection: a computational study exploring the potency and cytotoxicity profiles. J Enzyme Inhib Med Chem 2017,32(1),375-402","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1504\/IJBRA.2019.099575","volume":"15","author":"Talluri S.","year":"2019","unstructured":"Talluri S.; Computational protein design of bacteriocins based on structural scaffold of aureocin A53. Int J Bioinform Res Appl 2019,15(2),129-143","journal-title":"Int J Bioinform Res Appl"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1007\/s12272-015-0640-5","volume":"38","author":"Macalino S.J.Y.","year":"2015","unstructured":"Macalino S.J.Y.; Gosu V.; Hong S.; Choi S.; Role of computer-aided drug design in modern drug discovery. Arch Pharm Res 2015,38(9),1686-1701","journal-title":"Arch Pharm Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1021\/acs.jmedchem.5b02008","volume":"59","author":"Irwin J.J.","year":"2016","unstructured":"Irwin J.J.; Shoichet B.K.; Docking screens for novel ligands conferring new biology. J Med Chem 2016,59(9),4103-4120","journal-title":"J Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/cbdd.12193","volume":"82","author":"Cichero E.","year":"2013","unstructured":"Cichero E.; D\u2019Ursi P.; Moscatelli M.; Bruno O.; Orro A.; Rotolo C.; Milanesi L.; Fossa P.; Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors. Chem Biol Drug Des 2013,82(6),718-731","journal-title":"Chem Biol Drug Des"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1875692116666181108145230","volume":"16","author":"Mohanasundaram N.","year":"2018","unstructured":"Mohanasundaram N.; Sekhar T.; Computational studies of molecular targets regarding the adverse effects of isoniazid drug for tuberculosis. Curr Pharmacogenomics Person Med 2018,16(3),210-218","journal-title":"Curr Pharmacogenomics Person Med"},{"key":"ref=22","author":"Textbook of drug design and discovery. Str&#xF8;mgaard K.","year":"2017","unstructured":"Textbook of drug design and discovery. Str&#xF8;mgaard K.; Krogsgaard-Larsen P.; Madsen U.; 2017"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"Ashburn T.T.","year":"2004","unstructured":"Ashburn T.T.; Thor K.B.; Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683","journal-title":"Nat Rev Drug Discov"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","volume":"34","author":"Novac N.","year":"2013","unstructured":"Novac N.; Challenges and opportunities of drug repositioning. Trends Pharmacol Sci 2013,34(5),267-272","journal-title":"Trends Pharmacol Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","volume":"6","author":"Xu J.","year":"2020","unstructured":"Xu J.; Shi P-Y.; Li H.; Zhou J.; Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis 2020,6(5),909-915","journal-title":"ACS Infect Dis"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105932","volume":"55","author":"Colson P.","year":"2020","unstructured":"Colson P.; Rolain J-M.; Lagier J-C.; Brouqui P.; Raoult D.; Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020,55(4)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"Liu J.","year":"2020","unstructured":"Liu J.; Cao R.; Xu M.; Wang X.; Zhang H.; Hu H.; Li Y.; Hu Z.; Zhong W.; Wang M.; Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020,6,16","journal-title":"Cell Discov"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"Wang M.","year":"2020","unstructured":"Wang M.; Cao R.; Zhang L.; Yang X.; Liu J.; Xu M.; Shi Z.; Hu Z.; Zhong W.; Xiao G.; Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020,30(3),269-271","journal-title":"Cell Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"Gao J.","year":"2020","unstructured":"Gao J.; Tian Z.; Yang X.; Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020,14(1),72-73","journal-title":"Biosci Trends"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","author":"Gautret P.","year":"2020","unstructured":"Gautret P.; Lagier J.-C.; Parola P.; Hoang V. T.; Meddeb L.; Mailhe M.; Doudier B.; Courjon J.; Giordanengo V.; Vieira V. E.; Dupont H. T.; Honor&#xE9; S.; Colson P.; Chabri&#xE8;re E.; La Scola B.; Rolain J.-M.; Brouqui P.; Raoult D.; Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Int j antimicrobial agents 2020,105949","journal-title":"Int j antimicrobial agents"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","volume":"367","author":"Kupferschmidt K.","year":"2020","unstructured":"Kupferschmidt K.; Cohen J.; Race to find COVID-19 treatments accelerates. Science 2020,367(6485),1412-1413","journal-title":"Science"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"Anand K.","year":"2003","unstructured":"Anand K.; Ziebuhr J.; Wadhwani P.; Mesters J.R.; Hilgenfeld R.; Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003,300(5626),1763-1767","journal-title":"Science"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","volume":"63","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Lin D.; Kusov Y.; Nian Y.; Ma Q.; Wang J.; von Brunn A.; Leyssen P.; Lanko K.; Neyts J.; de Wilde A.; Snijder E.J.; Liu H.; Hilgenfeld R.; &#x3B1;-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J Med Chem 2020,63(9),4562-4578","journal-title":"J Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1093\/bioinformatics\/btaa224","volume":"36","author":"Liu S.","year":"2020","unstructured":"Liu S.; Zheng Q.; Wang Z.; Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus. Bioinformatics 2020,36(11),3295-3298","journal-title":"Bioinformatics"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-7069(06)16004-8","volume":"16","author":"Tong T.R.","year":"2006","unstructured":"Tong T.R.; Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). Perspect Med Virol 2006,16,43-95","journal-title":"Perspect Med Virol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Lin D.; Sun X.; Curth U.; Drosten C.; Sauerhering L.; Becker S.; Rox K.; Hilgenfeld R.; Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x3B1;-ketoamide inhibitors. Science 2020,368(6489),409-412","journal-title":"Science"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5582\/bst.2020.01030","volume":"14","author":"Wang Z.","year":"2020","unstructured":"Wang Z.; Chen X.; Lu Y.; Chen F.; Zhang W.; Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020,14(1),64-68","journal-title":"Biosci Trends"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"Cao B.","year":"2020","unstructured":"Cao B.; Wang Y.; Wen D.; Liu W.; Wang J.; Fan G.; Ruan L.; Song B.; Cai Y.; Wei M.; Li X.; Xia J.; Chen N.; Xiang J.; Yu T.; Bai T.; Xie X.; Zhang L.; Li C.; Yuan Y.; Chen H.; Li H.; Huang H.; Tu S.; Gong F.; Liu Y.; Wei Y.; Dong C.; Zhou F.; Gu X.; Xu J.; Liu Z.; Zhang Y.; Li H.; Shang L.; Wang K.; Li K.; Zhou X.; Dong X.; Qu Z.; Lu S.; Hu X.; Ruan S.; Luo S.; Wu J.; Peng L.; Cheng F.; Pan L.; Zou J.; Jia C.; Wang J.; Liu X.; Wang S.; Wu X.; Ge Q.; He J.; Zhan H.; Qiu F.; Guo L.; Huang C.; Jaki T.; Hayden F.G.; Horby P.W.; Zhang D.; Wang C.; A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020,382(19),1787-1799","journal-title":"N Engl J Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"5876","DOI":"10.1016\/j.bmcl.2007.08.031","volume":"17","author":"Ghosh A.K.","year":"2007","unstructured":"Ghosh A.K.; Xi K.; Grum-Tokars V.; Xu X.; Ratia K.; Fu W.; Houser K.V.; Baker S.C.; Johnson M.E.; Mesecar A.D.; Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett 2007,17(21),5876-5880","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"Wu C.","year":"2020","unstructured":"Wu C.; Liu Y.; Yang Y.; Zhang P.; Zhong W.; Wang Y.; Wang Q.; Xu Y.; Li M.; Li X.; Zheng M.; Chen L.; Li H.; Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020,10(5),766-788","journal-title":"Acta Pharm Sin B"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s41048-017-0045-8","volume":"4","author":"Xu X.","year":"2018","unstructured":"Xu X.; Huang M.; Zou X.; Docking-based inverse virtual screening: methods, applications, and challenges. Biophys Rep 2018,4(1),1-16","journal-title":"Biophys Rep"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Jin Z.","year":"2020","unstructured":"Jin Z.; Du X.; Xu Y.; Deng Y.; Liu M.; Zhao Y.; Zhang B.; Li X.; Zhang L.; Peng C.; Duan Y.; Yu J.; Wang L.; Yang K.; Liu F.; Jiang R.; Yang X.; You T.; Liu X.; Yang X.; Bai F.; Liu H.; Liu X.; Guddat L.W.; Xu W.; Xiao G.; Qin C.; Shi Z.; Jiang H.; Rao Z.; Yang H.; Structure of M from SARS-CoV-2 and discovery of its inhibitors. Nature 2020,582(7811),289-293","journal-title":"Nature"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.joim.2020.02.005","volume":"18","author":"Zhang D-H.","year":"2020","unstructured":"Zhang D-H.; Wu K-L.; Zhang X.; Deng S-Q.; Peng B.; In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med 2020,18(2),152-158","journal-title":"J Integr Med"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"e2000028","DOI":"10.1002\/minf.202000028","volume":"39","author":"Ton A.-T.","year":"2020","unstructured":"Ton A.-T.; Gentile F.; Hsing M.; Ban F.; Cherkasov A.; Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Molecular informatics 2020,39(8),e2000028","journal-title":"Molecular informatics"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","volume":"1607","author":"Burley S.K.","year":"2017","unstructured":"Burley S.K.; Berman H.M.; Kleywegt G.J.; Markley J.L.; Nakamura H.; Velankar S.; Protein Data Bank (PDB): The single global macromolecular structure archive. Methods Mol Biol 2017,1607,627-641","journal-title":"Methods Mol Biol"},{"key":"ref=46","author":"Liu X.","year":"2020","unstructured":"Liu X.; Zhang B.; Jin Z.; Yang H.; Rao Z.; The crystal structure of 2019-nCoV main protease in complex with an inhibitor N3 PDB ID 6LU7 2020 http:\/\/rcsb.org","journal-title":"PDB ID 6LU7"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"O\u2019Boyle N.M.","year":"2011","unstructured":"O\u2019Boyle N.M.; Banck M.; James C.A.; Morley C.; Vandermeersch T.; Hutchison G.R.; Open Babel: An open chemical toolbox. J Cheminform 2011,3,33","journal-title":"J Cheminform"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"Hanwell M.D.","year":"2012","unstructured":"Hanwell M.D.; Curtis D.E.; Lonie D.C.; Vandermeersch T.; Zurek E.; Hutchison G.R.; Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform 2012,4(1),17","journal-title":"J Cheminform"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S0968-0004(00)89080-5","volume":"20","author":"Sayle R.A.","year":"1995","unstructured":"Sayle R.A.; Milner-White E.J.; RASMOL: biomolecular graphics for all. Trends Biochem Sci 1995,20(9),374","journal-title":"Trends Biochem Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1093\/nar\/gki524","volume":"33","author":"Zhang Y.","year":"2005","unstructured":"Zhang Y.; Skolnick J.; TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 2005,33(7),2302-2309","journal-title":"Nucleic Acids Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"D1137","DOI":"10.1093\/nar\/gkx1088","volume":"46","author":"Siramshetty V.B.","year":"2018","unstructured":"Siramshetty V.B.; Eckert O.A.; Gohlke B-O.; Goede A.; Chen Q.; Devarakonda P.; Preissner S.; Preissner R.; SuperDRUG2: a one stop resource for approved\/marketed drugs. Nucleic Acids Res 2018,46(D1),D1137-D1143","journal-title":"Nucleic Acids Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/bioinformatics\/bti295","volume":"21","author":"Goede A.","year":"2005","unstructured":"Goede A.; Dunkel M.; Mester N.; Frommel C.; Preissner R.; SuperDrug: a conformational drug database. Bioinformatics 2005,21(9),1751-1753","journal-title":"Bioinformatics"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13321-018-0293-8","volume":"10","author":"H&#xE4;hnke V.D.","year":"2018","unstructured":"H&#xE4;hnke V.D.; Kim S.; Bolton E.E.; PubChem chemical structure standardization. J Cheminform 2018,10(1),36-76","journal-title":"J Cheminform"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"Wishart D.S.","year":"2018","unstructured":"Wishart D.S.; Feunang Y.D.; Guo A.C.; Lo E.J.; Marcu A.; Grant J.R.; Sajed T.; Johnson D.; Li C.; Sayeeda Z.; Assempour N.; Iynkkaran I.; Liu Y.; Maciejewski A.; Gale N.; Wilson A.; Chin L.; Cummings R.; Le D.; Pon A.; Knox C.; Wilson M.; DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018,46(D1),D1074-D1082","journal-title":"Nucleic Acids Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"Sterling T.","year":"2015","unstructured":"Sterling T.; Irwin J.J.; ZINC 15--Ligand Discovery for Everyone. J Chem Inf Model 2015,55(11),2324-2337","journal-title":"J Chem Inf Model"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/ci300604z","volume":"53","author":"Koes D.R.","year":"2013","unstructured":"Koes D.R.; Baumgartner M.P.; Camacho C.J.; Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model 2013,53(8),1893-1904","journal-title":"J Chem Inf Model"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12551-016-0247-1","volume":"9","author":"Pagadala N.S.","year":"2017","unstructured":"Pagadala N.S.; Syed K.; Tuszynski J.; Software for molecular docking: a review. Biophys Rev 2017,9(2),91-102","journal-title":"Biophys Rev"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv315","volume":"43","author":"Salentin S.","year":"2015","unstructured":"Salentin S.; Schreiber S.; Haupt V.J.; Adasme M.F.; Schroeder M.; PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res 2015,43(W1)","journal-title":"Nucleic Acids Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"Jeon S.","year":"2020","unstructured":"Jeon S.; Ko M.; Lee J.; Choi I.; Byun S.Y.; Park S.; Shum D.; Kim S.; Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 2020,64(7),e00819-e00820","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.25.965582","author":"Ko M.","year":"2020","unstructured":"Ko M.; Chang S.Y.; Byun S.Y.; Choi I.; Alexandry Orengiani A-L.P.H.; Shum D.; Min J-Y.; Windisch M.P.; Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. bioRxiv \u2022 [Online].2020","journal-title":"bioRxiv"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"Guo T.","year":"2020","unstructured":"Guo T.; Fan Y.; Chen M.; Wu X.; Zhang L.; He T.; Wang H.; Wan J.; Wang X.; Lu Z.; Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020,5(7),811-818","journal-title":"JAMA Cardiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jmb.2005.09.012","volume":"354","author":"Tan J.","year":"2005","unstructured":"Tan J.; Verschueren K.H.; Anand K.; Shen J.; Yang M.; Xu Y.; Rao Z.; Bigalke J.; Heisen B.; Mesters J.R.; Chen K.; Shen X.; Jiang H.; Hilgenfeld R.; pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J Mol Biol 2005,354(1),25-40","journal-title":"J Mol Biol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1021\/jm060999m","volume":"49","author":"Leach A.R.","year":"2006","unstructured":"Leach A.R.; Shoichet B.K.; Peishoff C.E.; Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 2006,49(20),5851-5855","journal-title":"J Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"12964","DOI":"10.1039\/C6CP01555G","volume":"18","author":"Wang Z.","year":"2016","unstructured":"Wang Z.; Sun H.; Yao X.; Li D.; Xu L.; Li Y.; Tian S.; Hou T.; Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power. Phys Chem Chem Phys 2016,18(18),12964-12975","journal-title":"Phys Chem Chem Phys"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1021\/acs.jcim.8b00312","volume":"58","author":"Gaillard T.","year":"2018","unstructured":"Gaillard T.; Evaluation of AutoDock and AutoDock Vina on the CASF-2013 Benchmark. J Chem Inf Model 2018,58(8),1697-1706","journal-title":"J Chem Inf Model"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"107532","DOI":"10.1016\/j.jmgm.2020.107532","volume":"96","author":"Masters L.","year":"2020","unstructured":"Masters L.; Eagon S.; Heying M.; Evaluation of consensus scoring methods for AutoDock Vina, smina and idock. J Mol Graph Model 2020,96,107532-107532","journal-title":"J Mol Graph Model"},{"key":"ref=68","volume":"8","author":"Rismanbaf A.","year":"2020","unstructured":"Rismanbaf A.; Potential Treatments for COVID-19; a Narrative Literature Review. Arch Acad Emerg Med 2020,8(1)","journal-title":"Arch Acad Emerg Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-1-4939-7201-2_18","volume":"1647","author":"Kontoyianni M.","year":"2017","unstructured":"Kontoyianni M.; Docking and Virtual Screening in Drug Discovery. Methods Mol Biol 2017,1647,255-266","journal-title":"Methods Mol Biol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s12539-019-00327-w","volume":"11","author":"Li J.","year":"2019","unstructured":"Li J.; Fu A.; Zhang L.; An Overview of Scoring Functions Used for Protein-Ligand Interactions in Molecular Docking. Interdiscip Sci 2019,11(2),320-328","journal-title":"Interdiscip Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijp.IJP_119_20","volume":"52","author":"Sarma P.","year":"2020","unstructured":"Sarma P.; Prajapat M.; Avti P.; Kaur H.; Kumar S.; Medhi B.; Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol 2020,52(1),1-5","journal-title":"Indian J Pharmacol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40265-018-0960-0","volume":"78","author":"Markham A.","year":"2018","unstructured":"Markham A.; Keam S.J.; Danoprevir: First Global Approval. Drugs 2018,78(12),1271-1276","journal-title":"Drugs"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40268-017-0222-8","volume":"18","author":"Garimella T.","year":"2018","unstructured":"Garimella T.; Tao X.; Sims K.; Chang Y-T.; Rana J.; Myers E.; Wind-Rotolo M.; Bhatnagar R.; Eley T.; LaCreta F.; AbuTarif M.; Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects. Drugs R D 2018,18(1),55-65","journal-title":"Drugs R D"},{"key":"ref=74","author":"Chen C.","year":"2020","unstructured":"Chen C.; Qi F.; Shi K.; Li Y.; Li J.; Chen Y.; Pan J.; Zhou T.; Lin X.; Zhang J.; Luo Y.; Li X.; Xia J.; Thalidomide Combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia Preprints 2020","journal-title":"Preprints"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"Mehta P.","year":"2020","unstructured":"Mehta P.; McAuley D.F.; Brown M.; Sanchez E.; Tattersall R.S.; Manson J.J.; COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet HLH Across Speciality Collaboration, UK2020,395(10229),1033-1034","journal-title":"Lancet"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.7150\/ijbs.45134","volume":"16","author":"Yi Y.","year":"2020","unstructured":"Yi Y.; Lagniton P.N.P.; Ye S.; Li E.; Xu R-H.; COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 2020,16(10),1753-1766","journal-title":"Int J Biol Sci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","volume":"395","author":"Shang L.","year":"2020","unstructured":"Shang L.; Zhao J.; Hu Y.; Du R.; Cao B.; On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020,395(10225),683-684","journal-title":"Lancet"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"Stebbing J.","year":"2020","unstructured":"Stebbing J.; Phelan A.; Griffin I.; Tucker C.; Oechsle O.; Smith D.; Richardson P.; COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020,20(4),400-402","journal-title":"Lancet Infect Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMe2005477","volume":"382","author":"Baden L.R.","year":"2020","unstructured":"Baden L.R.; Rubin E.J.; Covid-19 - The Search for Effective Therapy. N Engl J Med 2020,382(19),1851-1852","journal-title":"N Engl J Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.3390\/ijms20184331","volume":"20","author":"Pinzi L.","year":"2019","unstructured":"Pinzi L.; Rastelli G.; Molecular Docking: Shifting Paradigms in Drug Discovery. Int J Mol Sci 2019,20(18),4331","journal-title":"Int J Mol Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","volume":"17","author":"Zheng Y-Y.","year":"2020","unstructured":"Zheng Y-Y.; Ma Y-T.; Zhang J-Y.; Xie X.; COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020,17(5),259-260","journal-title":"Nat Rev Cardiol"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/184857","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184857\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/184857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T16:49:08Z","timestamp":1723394948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184857\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207323666200814132149","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202002.0418.v1","asserted-by":"object"},{"id-type":"doi","id":"10.20944\/preprints202002.0418.v2","asserted-by":"object"}]},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}